COVID-19 Update from iX Biopharma, read more here
The Xativa Hub is an Australian patient access gateway and an information hub for GPs and specialists to find out more about current research and treatment products available in Australia.
iX Biopharma is developing a range of sublingual wafers containing cannabidiol (CBD) by using its patented sublingual delivery technology, WaferiX™.
The wafers are formulated to contain a nano-emulsion of broad-spectrum hemp oil, which comprises:
A proprietary and patent-pending technology is used in the extraction & purification process of the hemp oil to preserve terpenes and plant lipids, while eliminating unwanted Delta-9-THC, waxes and chlorophyll.
iX is currently evaluating these CBD sublingual wafers for use in the treatment of certain conditions.
CBD suffers from poor oral bioavailability. Sublingual delivery of CBD is fast becoming the most preferred method of consuming CBD which allows a user to maximise the benefits of CBD.
IX's WaferiX™ sublingual delivery technology is a patented formulation produced by a proprietary freeze-drying technique. The porous and amorphous WaferiX™ matrix holding the active CBD is designed to rapidly collapse and release the nanoparticles of CBD within a minute of being in contact with saliva in the sublingual space. CBD is then rapidly transported across the sublingual membrane into the blood vessels for a rapid onset of action. Read more about how WaferiX™ works [here].
The benefits of CBD delivered using the WaferiX™ technology are:
It is a highly differentiated and superior offering compared to existing methods of delivering CBD. Existing delivery methods such as nasal sprays and oral capsules cause CBD to be inconsistently absorbed and is too variable or poorly bioavailable to be truly useful as a therapy.
WaferiX™ is a more elegant and convenient way to administer CBD, giving users a better experience.
Cannabis has a long and colourful history.
It is a plant of the Cannabaceae family and its medicinal properties have been known for millennia¹.
Cannabis was first thought to have originated from Central Asia and was used by many ancient societies.
In fact, indications for therapeutic use of cannabis were mentioned in the texts of the Indian Hindus, Assyrians, Greeks and Romans. Cannabis was described to have helped alleviate and treat many health ailments, including pain, depression, inflammation, appetite loss and asthma related problems et cetera.
The Cannabis plant contains two of the most prominent cannabinoids;
Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC).
Through the Endocannabinoid System in our body, CBD and THC interact to have various effects.
| CBD | THC |
|---|---|
| Non-intoxicating | Intoxicating |
| Anti-inflammatory and reduces pain | Anti-inflammatory and reduces pain |
| May reduce anxiety | May improve appetite |
| Anticonvulsant | Potentially reduces nausea |
| Regulate THC effects | May help with insomnia |
The endocannabinoid system (ECS) is a complex cell-signalling system found throughout our body³.
It consists of three key components, including:
Endocannabinoids
Receptors
Enzymes
Responsible for breaking down endocannabinoids once they have served their function
The endocannabinoid system plays a critical role in balancing many processes in our body, including immune response, appetite, sleep, et cetera.
1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com